Genflow Biosciences and CER Sign Master Service Agreement to Strengthen Long-Term R&D Collaboration

  • LONDON, UK / ACCESS Newswire / May 28, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to announce the signing of a Master Service Agreement (MSA) with CER Groupe (CER), a long-standing partner of the Company. CER is a private Belgian research center offering integrated bioproduction and pre-clinical services within a regulated ISO and GxP-compliant environment.